Health
Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain
Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care Patient testimonial now available here THE WOODLANDS, TX, May 05, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the rel
About this update from Autonomix Medical, Inc.
[{"type":"image","alt":"Autonomix Medical, Inc.","displaySize":"","headline":null,"caption":"Autonomix Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":174,"url":"https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yXZC_k658ygjAcliUe7Yow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6","width":300,"height":174}},"lazy":false},{"type":"text","content":"Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care","length":158,"tagName":"p"},{"type":"text","content":"Patient testimonial now available here","length":38,"tagName":"p"},{"type":"text","content":"THE WOODLANDS, TX, May 05, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the release of a new video testimonial from a patient participating in the initial phase of its first-in-human proof-of-concept trial (“PoC 1”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant nerves and mitigate pain in patients with severe pancreatic cancer pain. Access the patient testimonial here.","length":642,"tagName":"p"},{"type":"text","content":"“We are deeply grateful to the patients who have shared their experiences with us. Testimonials like this provide meaningful insight into the real-world impact our technology can have, particularly in improving quality of life and reducing dependence on pain medication,” said Brad Hauser, Chief Executive Officer of Autonomix. “Patients with late-stage pancreatic cancer face severe, often unrelenting pain. Data emerging from our ongoing study reinforce the significant burden this pain places on quality of life and point to a clear, unmet need for innovative interventional pain management solutions.”","length":605,"tagName":"p"},{"type":"text","content":"As previously announced, the Company enrolled twenty (20) patients in PoC 1, including the first five (5) “lead-in” patients. Based on consistent, corresponding evide...